These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 30734234)

  • 1. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
    Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
    Yoon H; Ye BD; Kang SB; Lee KM; Choi CH; Jo JY; Woo J; Cheon JH
    BMC Gastroenterol; 2024 Aug; 24(1):273. PubMed ID: 39160459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
    Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
    J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
    Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
    Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
    Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
    Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world clinical efficacy of tofacitinib in moderate-to-severe ulcerative colitis.
    Lopes SR; Martins C; Teixeira M; Tomás D
    World J Gastroenterol; 2024 Sep; 30(34):3929-3931. PubMed ID: 39350781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Endoscopic Outcomes Through 78 Weeks of Tofacitinib Therapy for Ulcerative Colitis in a US Cohort.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Oct; 30(10):1707-1713. PubMed ID: 37843044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials.
    Sandborn WJ; Panés J; D'Haens GR; Sands BE; Su C; Moscariello M; Jones T; Pedersen R; Friedman GS; Lawendy N; Chan G
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1541-1550. PubMed ID: 30476584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of tofacitinib safety in ulcerative colitis from the completed global clinical developmental program up to 9.2 years of drug exposure.
    Panés J; D'Haens GR; Sands BE; Ng SC; Lawendy N; Kulisek N; Guo X; Wu J; Vranic I; Panaccione R; Vermeire S
    United European Gastroenterol J; 2024 Jul; 12(6):793-801. PubMed ID: 38778549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
    World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
    Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
    Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
    Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
    Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.
    Chiorean M; Daperno M; Lees CW; Bonfanti G; Soudis D; Modesto I; Deuring JJ; Edwards RA
    Adv Ther; 2023 Oct; 40(10):4440-4459. PubMed ID: 37525075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Janus Kinase Inhibitors in the Management of Inflammatory Bowel Disease Following Liver Transplantation.
    Con D; Hilley P; Chin S; Corte C; Hafeez B; Testro A; De Cruz P; Choy M; Srinivasan A
    J Crohns Colitis; 2024 Sep; 18(9):1505-1509. PubMed ID: 38502366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
    Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
    Panés J; Vermeire S; Lindsay JO; Sands BE; Su C; Friedman G; Zhang H; Yarlas A; Bayliss M; Maher S; Cappelleri JC; Bushmakin AG; Rubin DT
    J Crohns Colitis; 2018 Jan; 12(2):145-156. PubMed ID: 29028981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sandborn WJ; Su C; Sands BE; D'Haens GR; Vermeire S; Schreiber S; Danese S; Feagan BG; Reinisch W; Niezychowski W; Friedman G; Lawendy N; Yu D; Woodworth D; Mukherjee A; Zhang H; Healey P; Panés J;
    N Engl J Med; 2017 May; 376(18):1723-1736. PubMed ID: 28467869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
    Allocca M; Catalano G; Savarino EV; Chaparro M; Levartovsky A; Michalopoulos G; Viazis N; Fousekis FS; Psistakis A; Noviello D; Nascimento CND; Caron B; Kitsou V; Bamias G; García MJ; Zacharopoulou E; Foteinogiannopoulou K; D'Amico F; Koutroubakis I; Ellul P; Tzouvala M; Peyrin-Biroulet L; Torres J; Caprioli F; Karmiris K; Theodoropoulou A; Katsanos KH; Christodoulou DK; Mantzaris GJ; Kopylov U; Gisbert JP; Danese S; Magro F; Carla F; Fiorino G
    United European Gastroenterol J; 2024 Jun; 12(5):543-551. PubMed ID: 38419274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.